Coherus BioSciences Inc.
1.45
-0.02 (-1.36%)
At close: Jan 14, 2025, 3:59 PM
1.50
3.45%
Pre-market Jan 15, 2025, 08:46 AM EST

Coherus BioSciences Statistics

Share Statistics

Coherus BioSciences has 115.21M shares outstanding. The number of shares has increased by 3.46% in one year.

Shares Outstanding 115.21M
Shares Change (YoY) n/a
Shares Change (QoQ) 0%
Owned by Institutions (%) n/a
Shares Floating 110.59M
Failed to Deliver (FTD) Shares 249.69K
FTD / Avg. Volume 4.93%

Short Selling Information

The latest short interest is 31.07M, so 26.97% of the outstanding shares have been sold short.

Short Interest 31.07M
Short % of Shares Out 26.97%
Short % of Float 28.1%
Short Ratio (days to cover) 3.23

Valuation Ratios

The PE ratio is -1.32 and the forward PE ratio is -3.05.

PE Ratio -1.32
Forward PE -3.05
PS Ratio 1.22
Forward PS 0.6
PB Ratio -1.62
P/FCF Ratio -1.79
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Coherus BioSciences Inc. has an Enterprise Value (EV) of 691.51M.

EV / Earnings -2.91
EV / Sales 2.69
EV / EBITDA -3.57
EV / EBIT -3.4
EV / FCF -3.95

Financial Position

The company has a current ratio of 1.43, with a Debt / Equity ratio of -2.49.

Current Ratio 1.43
Quick Ratio 1.24
Debt / Equity -2.49
Total Debt / Capitalization 167.3
Cash Flow / Debt -0.36
Interest Coverage -5.01

Financial Efficiency

Return on equity (ROE) is 1.23% and return on capital (ROIC) is -70.59%.

Return on Equity (ROE) 1.23%
Return on Assets (ROA) -0.38%
Return on Capital (ROIC) -70.59%
Revenue Per Employee 1.09M
Profits Per Employee -1.01M
Employee Count 235
Asset Turnover 0.41
Inventory Turnover 2.6

Taxes

Income Tax -380.00K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -38.3% in the last 52 weeks. The beta is 0.69, so Coherus BioSciences 's price volatility has been higher than the market average.

Beta 0.69
52-Week Price Change -38.3%
50-Day Moving Average 1.28
200-Day Moving Average 1.5
Relative Strength Index (RSI) 48.85
Average Volume (20 Days) 5.06M

Income Statement

In the last 12 months, Coherus BioSciences had revenue of 257.24M and earned -237.89M in profits. Earnings per share was -2.53.

Revenue 257.24M
Gross Profit 94.46M
Operating Income -203.20M
Net Income -237.89M
EBITDA -193.94M
EBIT -203.20M
Earnings Per Share (EPS) -2.53
Full Income Statement

Balance Sheet

The company has 102.89M in cash and 480.84M in debt, giving a net cash position of -377.95M.

Cash & Cash Equivalents 102.89M
Total Debt 480.84M
Net Cash -377.95M
Retained Earnings -1.58B
Total Assets 505.00M
Working Capital 73.46M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -174.88M and capital expenditures -286.00K, giving a free cash flow of -175.17M.

Operating Cash Flow -174.88M
Capital Expenditures -286.00K
Free Cash Flow -175.17M
FCF Per Share -1.86
Full Cash Flow Statement

Margins

Gross margin is 36.72%, with operating and profit margins of -78.99% and -92.48%.

Gross Margin 36.72%
Operating Margin -78.99%
Pretax Margin -92.62%
Profit Margin -92.48%
EBITDA Margin -75.39%
EBIT Margin -78.99%
FCF Margin -68.09%

Dividends & Yields

CHRS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -174.48%
FCF Yield -104.86%
Dividend Details

Analyst Forecast

The average price target for CHRS is $7, which is 382.8% higher than the current price. The consensus rating is "Buy".

Price Target $7
Price Target Difference 382.8%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Scores

Altman Z-Score -3.93
Piotroski F-Score 3